Simulation of Effectiveness of Secondary Risk-Reducing Strategies in Carriers of Pathogenic Variants of BRCA1 and BRCA2 with Unilateral Primary Breast Cancer after Breast-Conserving Surgery

Maksimenko, J. (Speaker)
Pedro Pereira Rodrigues (Co-author)
Nakazawa (Miklasevica), M. (Co-author)
David Pinto (Co-author)
Trofimovičs, G. (Co-author)
Miklaševičs, E. (Speaker)
Gardovskis, J. (Co-author)
Maria João Cardoso (Co-author)
Fatima Cardoso (Co-author)

Rīga Stradiņš University

Activity: Talk or presentation types › Oral presentation

Description

The aim of the present study was to develop a personalized risk management decision support tool for carriers of pathogenic variant of BRCA1 and BRCA2 who underwent breast-conserving therapy for unilateral early stage breast cancer. . We predicted the 40 -year overall survival of different risk-reducing strategies for 144 cohorts of women defined by the type of pathogenic variant of BRCA1 and BRCA2, age at primary breast cancer diagnosis, breast cancer subtype, stage of primary breast cancer, presence or absence of adjuvant chemotherapy.. Absence of adjuvant chemotherapy was the most powerful factor that was linked to dramatic decline in survival for breast cancer patients with pathogenic variant of BRCA1 and
BRCA2. There was a negligible decline in the mortality in carriers of pathogenic variants of BRCA1 and BRCA2 with triple-negative breast cancer, who received no chemotherapy and underwent any secondary risk-reducing strategy compared to surveillance. However, most of carriers of pathogenic variant of BRCA1 and BRCA2 with triple-negative breast cancer in I stage profited from bilateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy/ or just risk-reducing salpingo-oophorectomy. Most carriers of pathogenic variant of BRCA1 and BRCA2 with luminal breast cancer in stage I-II unilateral breast cancer, profited from bilateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy. Most of older patients with BRCA1 and BRCA2 pathogenic variant in exon 12-24/25 with luminal breast cancer may gain a similar survival benefit from other risk-reducing strategies or surveillance. . Our study showed that it is mandatory to take into account the complex interplay between the type of BRCA1 and BRCA2 pathogenic variant, age at primary breast cancer diagnosis, breast cancer subtype and stage and received systemic treatment.

Period	29 Mar 2023 → 31 Mar 2023
Event title	RSU International Research Conference 2023: Knowledge for Use in Practice
Event type	Conference
Organiser	Rīga Stradiņš University
Location	Riga, LatviaShow on map
Degree of Recognition	International